<DOC>
	<DOCNO>NCT02599077</DOCNO>
	<brief_summary>Project Summary Endometriosis disease high prevalence primarily affect woman childbearing age . This condition bring important physical emotional burden sufferer require proper timely medical management . At present several first-line drug available management symptom disease control . In world literature report several study demonstrate effectiveness different group drug oral contraceptive , progestin , GnRH analogues danazol . Within available scientific evidence extensively describe benefit new progestin Dienogest , demonstrate favorable safety profile efficacy along significant reduction symptom disease anti-inflammatory , antiproliferative antiagiogénicas endometrial tissue . However , although therapeutic property drug know , study need compare effectiveness effectiveness therapeutic agent oral contraceptive . That main objective study evaluate impact Dienogest 2 mg / day compare combined oral contraceptive ( levonorgestrel + ethinyl estradiol ) size endometriomas diagnose transvaginal ultrasonography 50 woman diameter less 4 centimeter , medical management give one year University Hospital Fundación Santa Fe de Bogota . The study conduct clinical trial , randomize , single-blind observer . The result analyze finding study serve tool define new therapeutic conduct management endometriosis .</brief_summary>
	<brief_title>Impact vs. Dienogest : A Combined Oral Contraceptive Size Endometriomas</brief_title>
	<detailed_description>Problem Justification : Endometriosis define presence endometrial tissue outside uterine cavity , induce chronic inflammatory response . It common problem affect 6-10 % woman reproductive age , 50-60 % woman adolescent pelvic pain nearly 50 % woman infertility . characterize abdominal pain , back pain , pain sex , dysfunctional uterine bleed infertility . Being common condition among woman childbearing age , often go undiagnosed many year . This delay diagnosis due variability symptom lack tools accurate diagnosis available primary care , major burden quality life patient symptomatic . The diagnosis endometriosis start clinical history physical examination transvaginal ultrasound proven useful diagnosis ovarian endometriomas differential diagnosis ovarian mass . Histologically lesion identify endometriosis resemble endometrial tissue place outside endometrium , proliferate response hormonal change occur menstruation , cause increase pain bleeding . Pharmacological agent preferred first-line treatment manage symptom . Among , oral contraceptive use treat symptom menorrhagia dysmenorrhoea associate endometriosis , affect endometrial line decrease proliferation endometrial tissue menstrual cycle , shorten number day endometrial tissue appear , reduce amount consistency bleeding . Another drug use manage condition Dienogest , proven superior treatment placebo effect comparable drug use management endometriosis , progestins GnRH analogue . All drug treatment endometriosis effective reduce size number lesion , intend cure disease eliminate injury peritoneal cavity . Another management option surgery , reserve specific case patient respond drug treatment . Endometriosis disease imposes severe financial burden society , physical emotional toll people . Therefore important understand , education medical staff disease . According statistic service approximately 200 woman year treat reproductive age average 50 endometriomas since clear scientific evidence impact combine oral contraceptive compare use Dienogest , objective study determine impact Dienogest 2 mg / day compare combined oral contraceptive ( levonorgestrel + ethinyl estradiol ) reduce size endometriomas diagnose transvaginal ultrasound woman diameter small 4 centimeter thereof , Hospital Universitario Fundación Santa Fe de Bogota . Goals : General : Determine impact Dienogest 2 mg / day compare combined oral contraceptive ( levonorgestrel + ethinyl estradiol 0.10 mg - 0.02 mg / day ) treatment endometriomas diagnose transvaginal ultrasound woman small diameter 4 centimeter thereof , University Hospital Fundación Santa Fe de Bogota . Specific : - Determine Decreasing size endometriomas Dienogest use medical treatment endometriosis . - Determine Decreased endometriomas size use combine oral contraceptive medical treatment endometriosis . - Determine Through ultrasound scan diagnostic tool impact reduction size endometriomas . - Compare The effect Dienogest v combine oral contraceptive time . Methodology Type study Experimental study single-blind randomized clinical trial observer . Universe Endometriomas patient diameter small 4 centimeter diagnose transvaginal ultrasound patient present Santa Fe de Bogota Foundation 2015 2016 . Sample size To analyze case endometriomas medical management v Dienogest use oral contraceptive , sample size calculate use estimate sample size comparison proportion 2 sample follow information : N : 200 Proportion : 1.6 % , estimate prevalence endometriosis 8 % 20 % endometriomas . Confidence level : 95 % Z2 : 1.96 Alpha error 5 % No : 22 Estimated loss : 10 % Sample require : N1 : 25 N2 : 25</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Women Of childbearing age ( period ) , without desire fertility , without treatment endometriosis past three month , ultrasound diagnosis endometrioma ( unilateral bilateral ) minor diameter 4 centimeter . Those go surgical procedure choose instruct follow medical management . No contraindication oral contraceptive use , rating eligibility criterion WHO 1 ( restriction use circumstance ) 2 ( advantage use method generally outweigh risk , usually use ) . And enter University Hospital Fundación Santa Fe de Bogota . Intercurrent cardiovasculardisease history ( arterial thrombosis current previous venous thromboembolism , thrombophilic genetic disease ) , smoke , obesity , kidney failure , SLE , diagnose suspect autoimmune disease hypertension . If history migraine accompany eg visual symptom , slur speech weakness numbness part body . If diabetes mellitus blood vessel . If pancreatitis ( inflammation pancreas ) associate high level fatty substance blood . If jaundice ( yellow skin ) severe liver disease . If cancer may grow influence sex hormone ( eg breast genitals ) . If liver tumor , benign malignant . If unexplained vaginal bleeding . If pregnant think might . If hypersensitive ( allergic ) ethinyl estradiol , levonorgestrel , dienogest part .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>oral contraceptive</keyword>
	<keyword>endometrioma</keyword>
	<keyword>dienogest</keyword>
</DOC>